Shin Egawa

Author PubWeight™ 68.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Replication of prostate cancer risk loci in a Japanese case-control association study. J Natl Cancer Inst 2009 2.39
2 Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007 2.34
3 Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 2012 1.59
4 High molecular mass proteome of androgen-independent prostate cancer. Proteomics 2005 1.54
5 The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int 2011 1.54
6 Pathophysiology of urinary incontinence in murine models. Int J Urol 2012 1.48
7 Deaths within 12 months after (125)I implantation for brachytherapy of prostate cancer: an investigation of radiation safety issues in Japan (2003-2010). Brachytherapy 2011 1.38
8 Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A 2012 1.34
9 Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013 1.32
10 Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev 2013 1.17
11 Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics 2010 1.15
12 Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol 2009 1.13
13 Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008 1.06
14 Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 2002 1.03
15 Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 2007 0.97
16 Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging. Int J Urol 2006 0.97
17 Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 2005 0.95
18 Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005 0.95
19 Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003 0.94
20 Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int 2011 0.93
21 Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res 2004 0.92
22 Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. Int J Urol 2013 0.90
23 Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother 2013 0.90
24 Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). Int J Urol 2008 0.89
25 Prostatic cystadenoma presenting as a large multilocular mass. Int J Urol 2002 0.89
26 Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer. Int J Cancer 2008 0.89
27 Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int 2008 0.89
28 Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2012 0.87
29 Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial. World J Urol 2012 0.87
30 Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2010 0.87
31 Ammonium acid urate urolithiasis in Japan. Int J Urol 2006 0.87
32 Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathol Int 2012 0.87
33 Changes in quality of life in first year after radical prostatectomy by retropubic, laparoscopic, and perineal approach: Multi-institutional longitudinal study in Japan. Urology 2006 0.87
34 Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002 0.86
35 The role of lymph node dissection in the management of prostate cancer. Int J Clin Oncol 2011 0.86
36 Role of alpha2-adrenoceptors and glutamate mechanisms in the external urethral sphincter continence reflex in rats. J Urol 2009 0.85
37 Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers. Genes Chromosomes Cancer 2006 0.85
38 In situ gene therapy for prostate cancer. Curr Gene Ther 2005 0.85
39 Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. Am J Physiol Regul Integr Comp Physiol 2008 0.84
40 Recovery of quality of life in year after laparoscopic or retropubic radical prostatectomy: a multi-institutional longitudinal study. Urology 2005 0.83
41 Efficacy and morbidity of transrectal ultrasound-guided 12-core biopsy for detection of prostate cancer in Japanese men. Int J Urol 2005 0.83
42 Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol 2002 0.83
43 Lateral view dissection of the prostato-urethral junction to reduce positive apical margin in laparoscopic radical prostatectomy. Int J Urol 2009 0.82
44 Upfront transection and subsequent ligation of the dorsal vein complex during laparoscopic radical prostatectomy. Int J Urol 2010 0.81
45 The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 2002 0.81
46 Transient receptor potential A1 receptor-mediated neural cross-talk and afferent sensitization induced by oxidative stress: implication for the pathogenesis of interstitial cystitis/bladder pain syndrome. Int J Urol 2012 0.81
47 Physiological effects of human muscle-derived stem cell implantation on urethral smooth muscle function. Int Urogynecol J Pelvic Floor Dysfunct 2008 0.81
48 [Changes of edema associated with I-125 prostate brachytherapy]. Nihon Igaku Hoshasen Gakkai Zasshi 2005 0.80
49 RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer. Int J Cancer 2005 0.80
50 Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. Jpn J Clin Oncol 2002 0.80
51 Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency. J Clin Lab Anal 2008 0.80
52 Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder. Biomed Res 2014 0.80
53 Nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan. J Infect Chemother 2013 0.80
54 [Clinical study of laparoscopic adrenalectomy for adrenal pheochromocytoma]. Hinyokika Kiyo 2009 0.80
55 Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy). J Radiat Res 2013 0.80
56 [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer]. Nihon Hinyokika Gakkai Zasshi 2006 0.79
57 [Radiation therapy for bone metastasis from renal cell carcinoma with emphasis on local control]. Hinyokika Kiyo 2007 0.79
58 Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 2011 0.78
59 Morbidity of laparoscopic radical prostatectomy: summary of early multi-institutional experience in Japan. Int J Urol 2003 0.78
60 Time-dependent changes in bladder function and plantar sensitivity in a rat model of fibromyalgia syndrome induced by hydrochloric acid injection into the gluteus. BJU Int 2011 0.77
61 Urethral compensatory mechanisms to maintain urinary continence after pudendal nerve injury in female rats. Int Urogynecol J 2011 0.77
62 Mid-term outcome of permanent prostate iodine-125 brachytherapy in Japanese patients. Int J Urol 2013 0.77
63 Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 2006 0.77
64 [The prevalence of hypertension after adrenalectomy in patients with primary aldosteronism]. Hinyokika Kiyo 2013 0.76
65 The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy. BJU Int 2007 0.76
66 Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with alpha2-macroglobulin deficiency. Clin Lab 2012 0.76
67 Patterns of failure and influence of potential prognostic factors after surgery in transitional cell carcinoma of the upper urinary tract. Int J Clin Oncol 2009 0.76
68 Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland. Int J Urol 2006 0.76
69 A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient. Prostate 2009 0.75
70 What is needed for improved patient care in upper urinary tract urothelial carcinoma? Eur Urol 2012 0.75
71 Laparoscopic radical prostatectomy as our bridge to the future? Eur Urol 2008 0.75
72 Nondestructive testing in urologic oncology. Eur Urol 2009 0.75
73 Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates. Eur Urol 2013 0.75
74 α(2)-Adrenoceptors as a new target for stress urinary incontinence. Low Urin Tract Symptoms 2009 0.75
75 [Prostate-specific antigen and its related parameters in detecting prostate cancer]. Gan To Kagaku Ryoho 2003 0.75
76 Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: a randomized controlled trial for men with prostate cancer. Int J Urol 2011 0.75
77 [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. Hinyokika Kiyo 2008 0.75
78 Results of central pathology review of prostatic biopsies in a contemporary series from a phase III, multicenter, randomized controlled trial (SHIP0804). Pathol Int 2015 0.75
79 Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: multicenter cohort study. J Infect Chemother 2013 0.75
80 [Preoperative prediction of remnant renal function in nephron-sparing surgery: the usefulness of 99mTc-mercapto-acetyl-triglycine scintigraphy]. Hinyokika Kiyo 2008 0.75
81 [CLINICAL CHARACTERISTICS OF T1 HIGH GRADE BLADDER CANCER]. Nihon Hinyokika Gakkai Zasshi 2015 0.75
82 Clinicopathological characteristics of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 2012 0.75
83 [Condyloma acuminatum which developed in the neourethra post-urethroplasty for hypospasias; a case report]. Kansenshogaku Zasshi 2014 0.75
84 [New marker proteins for prostate cancer]. Nihon Rinsho 2011 0.75
85 Thoracoscopic transdiaphragmatic adrenalectomy for isolated locally recurrent adrenal carcinoma. Int J Urol 2005 0.75
86 IJU this issue. Int J Urol 2016 0.75
87 Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study. Int J Urol 2003 0.75
88 [New biomarkers for the prostate cancer]. Nihon Rinsho 2012 0.75
89 Shrinkage of prostate volume in sunitinib-treated patients with renal cell carcinoma. Jpn J Clin Oncol 2013 0.75
90 [One-week effects of Tamsulosin on benign prostatic hyperplasia assessed with a daily symptom score]. Hinyokika Kiyo 2009 0.75
91 [A case of papillary renal cell carcinoma type 2 resistant to sunitinib responded to second line therapy with axitinib]. Nihon Hinyokika Gakkai Zasshi 2014 0.75
92 [RISK FACTORS FOR INTRAVESICAL RECURRENCE AFTER SURGICAL MANAGEMENT OF UROTHERIAL CARCINOMA OF THE UPPER URINARY TRACT]. Nihon Hinyokika Gakkai Zasshi 2015 0.75
93 Enhancement of antimicrobial activities of cefteram or clavulanic acid/amoxicillin against cefixime-resistant Neisseria gonorrhoeae in the presence of clarithromycin or azithromycin. J Infect Chemother 2006 0.75
94 [Roles of BPH impact index in the evaluation of impaired urination in patients with BPH]. Nihon Hinyokika Gakkai Zasshi 2005 0.75
95 Decision making using hybrid rough sets and neural networks. Int J Neural Syst 2002 0.75
96 Cross-sensitization mechanisms between colon and bladder via transient receptor potential A1 stimulation in rats. Int Urogynecol J 2014 0.75
97 [Laparoscopic radical prostatectomy (LRP)]. Nihon Rinsho 2016 0.75
98 IJU this issue. Int J Urol 2016 0.75
99 Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis. Anticancer Res 2013 0.75
100 IJU this issue: An academic journal functions as a vector to convey messages and information among researchers around the world who share an interest. Int J Urol 2011 0.75
101 Associations of IgG N-linked oligosaccharide chains and proteases in sera of prostate cancer patients with and without alpha2-macroglobulin deficiency. J Clin Lab Anal 2009 0.75
102 [Solitary adrenal metastasis of bladder carcinoma : a case report]. Hinyokika Kiyo 2012 0.75
103 [A case of pheochromocytoma associated with incidental multiple renal cell carcinoma originating from acquired cystic disease of the kidney in hemodialysis]. Hinyokika Kiyo 2006 0.75
104 [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker]. Hinyokika Kiyo 2008 0.75
105 [Simultaneous renal cell carcinoma and urothelial carcinoma in ipsilateral kidney, report of two cases]. Hinyokika Kiyo 2006 0.75
106 IJU this issue. Int J Urol 2015 0.75
107 Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol 2014 0.75
108 Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol 2009 0.75
109 [A case report of placenta percreta with bladder invasion]. Hinyokika Kiyo 2012 0.75
110 IJU this issue. Int J Urol 2014 0.75
111 Current environment surrounding clinical studies in Japan. Urol Oncol 2009 0.75
112 Fifth joint meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association. Int J Urol 2010 0.75
113 [Clinical study on postoperative steroid hormone replacement for preclinical Cushing's syndrome]. Nihon Hinyokika Gakkai Zasshi 2009 0.75
114 [Questionnaire survey on the theory of antimicrobial prophylaxis in urologic surgery]. Hinyokika Kiyo 2004 0.75
115 [Emphysematous pyelonephritis and cystitis concurrence; A case report]. Kansenshogaku Zasshi 2011 0.75